Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS;...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Biologics Less Effective for Ankylosing Spondylitis in Women Biologics Less Effective for Ankylosing Spondylitis in Women
Women and men with ankylosing spondylitis respond differently to TNF inhibitor therapy, and researchers are trying to determine why that is.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Stromal Vascular Fraction Treatment for Osteoarthritis Stromal Vascular Fraction Treatment for Osteoarthritis
A novel stem-cell therapy with stromal vascular fraction resulted in dramatic improvements to this patient ' s osteoarthritis and comorbidities including ankylosing spondylitis, depression, and fatigue.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news
Ankylosing Spondylitis: No Special Infection Risk from Treatment
(MedPage Today) -- DMARDs, TNF inhibitors appear safe in this regard (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 8, 2018 Category: Primary Care Source Type: news
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
INDIANAPOLIS, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and eff... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news
Risankizumab Fails in Spine Disease (CME/CE)
(MedPage Today) -- Blocking IL-23 not a winning strategy in ankylosing spondylitis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 27, 2018 Category: Primary Care Source Type: news
Ankylosing Spondylitis Patients at Risk for Self-Harm Ankylosing Spondylitis Patients at Risk for Self-Harm
People with this painful condition that affects the spine are at higher risk of harming themselves, a large study confirms; however, the mental health effects of the disease are often ignored.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Combining NSAIDs and TNFi may reduce radiographic progression in ankylosing spondylitis
(European League Against Rheumatism) The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2018 Category: International Medicine & Public Health Source Type: news
Significant increase in self-harm attempts following ankylosing spondylitis diagnosis
(European League Against Rheumatism) The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate a significantly increased rate of self-harm attempts in inflammatory arthritis (IA), particularly following a diagnosis of Ankylosing Spondylitis (AS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2018 Category: International Medicine & Public Health Source Type: news
Imagine Dragons' Dan Reynolds opens up on health struggles
Reynolds has ankylosing spondylitis, an inflammatory disease that once caused the singer crippling amounts of pain (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 11, 2018 Category: Consumer Health News Source Type: news
Managing Morbidity and Treatment-Related Toxicity in AS Managing Morbidity and Treatment-Related Toxicity in AS
Find out more about the morbidities associated with ankylosing spondylitis and its treatment, and learn how to best manage them.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Efficacy, Safety, and Tolerability of Secukinumab in AS Efficacy, Safety, and Tolerability of Secukinumab in AS
Is secukinumab a safe and effective treatment choice for patients with ankylosing spondylitis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
EMA Committee Backs Remicade Biosimilar Zessly EMA Committee Backs Remicade Biosimilar Zessly
The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn ' s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and e... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news
Factors Affecting Blood Loss During Total Hip Arthroplasty in Patients With Ankylosing Spondylitis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 17, 2018 Category: Orthopaedics Tags: CME Article Source Type: news
